25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Novartis AG
Buy, Hold or Sell?

Let's analyze Novartis together

I guess you are interested in Novartis AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Novartis AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Novartis AG

I send you an email if I find something interesting about Novartis AG.

1. Quick Overview

1.1. Quick analysis of Novartis (30 sec.)










1.2. What can you expect buying and holding a share of Novartis? (30 sec.)

How much money do you get?

How much money do you get?
₱0.18
When do you have the money?
1 year
How often do you get paid?
70.0%

What is your share worth?

Current worth
₱20.70
Expected worth in 1 year
₱16.63
How sure are you?
76.7%

+ What do you gain per year?

Total Gains per Share
₱-0.32
Return On Investment
0.0%

For what price can you sell your share?

Current Price per Share
₱2,138.50
Expected price per share
₱2,149 - ₱2,237
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Novartis (5 min.)




Live pricePrice per Share (EOD)
₱2,138.50
Intrinsic Value Per Share
₱63.89 - ₱74.52
Total Value Per Share
₱84.58 - ₱95.21

2.2. Growth of Novartis (5 min.)




Is Novartis growing?

Current yearPrevious yearGrowGrow %
How rich?$2b$2.7b-$707.3m-34.6%

How much money is Novartis making?

Current yearPrevious yearGrowGrow %
Making money$4b$1.9b$2.1b52.7%
Net Profit Margin33.5%14.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Novartis (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Novartis?

Welcome investor! Novartis's management wants to use your money to grow the business. In return you get a share of Novartis.

First you should know what it really means to hold a share of Novartis. And how you can make/lose money.

Speculation

The Price per Share of Novartis is ₱2,139. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novartis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novartis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₱20.70. Based on the TTM, the Book Value Change Per Share is ₱-1.02 per quarter. Based on the YOY, the Book Value Change Per Share is ₱-1.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₱0.94 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novartis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.600.1%1.980.1%0.900.0%1.460.1%1.450.1%
Usd Book Value Change Per Share0.060.0%-0.050.0%-0.050.0%-0.010.0%0.030.0%
Usd Dividend Per Share0.060.0%0.050.0%0.040.0%0.090.0%0.110.0%
Usd Total Gains Per Share0.120.0%0.000.0%-0.010.0%0.080.0%0.140.0%
Usd Price Per Share90.70-84.31-80.67-85.87-80.15-
Price to Earnings Ratio14.15-14.54-23.52-21.56-19.88-
Price-to-Total Gains Ratio769.32--253.41--5,230.31--449.27--192.18-
Price to Book Ratio89.44-84.59-62.30-72.33-62.40-
Price-to-Total Gains Ratio769.32--253.41--5,230.31--449.27--192.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share104.7865
Number of shares9
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.09
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share0.000.08
Gains per Quarter (9 shares)-0.040.70
Gains per Year (9 shares)-0.142.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12-2-103-0-7
23-4-106-1-4
35-5-1010-1-1
47-7-1013-22
58-9-1016-25
610-11-1019-38
712-13-1023-311
813-14-1026-414
915-16-1029-417
1017-18-1032-420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%30.00.00.0100.0%30.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%10.010.00.050.0%18.012.00.060.0%18.012.00.060.0%
Dividend per Share2.00.02.050.0%6.00.06.050.0%12.00.08.060.0%21.00.09.070.0%21.00.09.070.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%14.06.00.070.0%23.07.00.076.7%23.07.00.076.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Novartis AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.212-1.017+184%-1.025+185%-0.253+121%0.690+76%
Book Value Per Share--20.69720.415+1%26.494-22%24.633-16%27.890-26%
Current Ratio--0.9310.983-5%1.175-21%1.027-9%1.047-11%
Debt To Asset Ratio--0.5700.585-3%0.512+11%0.546+4%0.529+8%
Debt To Equity Ratio--1.3321.450-8%1.054+26%1.227+9%1.156+15%
Dividend Per Share--1.1940.936+27%0.865+38%1.836-35%2.240-47%
Eps--32.70640.421-19%18.465+77%29.713+10%29.631+10%
Free Cash Flow Per Share--2.0481.435+43%1.494+37%1.322+55%1.322+55%
Free Cash Flow To Equity Per Share--0.468-0.178+138%-1.059+326%-0.359+177%-0.359+177%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--74.517--------
Intrinsic Value_10Y_min--63.886--------
Intrinsic Value_1Y_max--5.874--------
Intrinsic Value_1Y_min--5.769--------
Intrinsic Value_3Y_max--18.864--------
Intrinsic Value_3Y_min--17.984--------
Intrinsic Value_5Y_max--33.317--------
Intrinsic Value_5Y_min--30.819--------
Market Cap4275438929216.000+12%3747658019259.0003511313625319.482+7%3483971105498.773+8%3804360825462.880-1%3470798872784.149+8%
Net Profit Margin--0.2520.335-25%0.144+76%0.245+3%0.240+5%
Operating Margin----0%0.190-100%0.203-100%0.208-100%
Operating Ratio--0.9351.015-8%1.118-16%1.086-14%1.100-15%
Pb Ratio103.326+13%89.43984.594+6%62.298+44%72.325+24%62.397+43%
Pe Ratio16.347+13%14.15014.543-3%23.521-40%21.555-34%19.882-29%
Price Per Share2138.500+13%1851.0801720.617+8%1646.305+12%1752.351+6%1635.684+13%
Price To Free Cash Flow Ratio261.006+13%225.926413.946-45%285.743-21%379.355-40%252.904-11%
Price To Total Gains Ratio888.775+13%769.321-253.406+133%-5230.311+780%-449.266+158%-192.180+125%
Quick Ratio--0.3170.258+23%0.504-37%0.404-21%0.382-17%
Return On Assets--0.6790.827-18%0.342+99%0.549+24%0.514+32%
Return On Equity--1.5871.904-17%0.710+123%1.192+33%1.096+45%
Total Gains Per Share--2.406-0.081+103%-0.160+107%1.583+52%2.930-18%
Usd Book Value--2053198000.0002041499250.000+1%2748826500.000-25%2620186800.000-22%2870287700.000-28%
Usd Book Value Change Per Share--0.059-0.050+184%-0.050+185%-0.012+121%0.034+76%
Usd Book Value Per Share--1.0141.000+1%1.298-22%1.207-16%1.367-26%
Usd Dividend Per Share--0.0580.046+27%0.042+38%0.090-35%0.110-47%
Usd Eps--1.6031.981-19%0.905+77%1.456+10%1.452+10%
Usd Free Cash Flow--203203000.000143508750.000+42%155207500.000+31%126211750.000+61%84141166.667+142%
Usd Free Cash Flow Per Share--0.1000.070+43%0.073+37%0.065+55%0.065+55%
Usd Free Cash Flow To Equity Per Share--0.023-0.009+138%-0.052+326%-0.018+177%-0.018+177%
Usd Market Cap209496507531.584+12%183635242943.691172054367640.655+7%170714584169.440+8%186413680447.681-1%170069144766.423+8%
Usd Price Per Share104.787+13%90.70384.310+8%80.669+12%85.865+6%80.149+13%
Usd Profit--3244542546.0004041934356.250-20%1911141512.000+70%3148535672.450+3%3061224892.600+6%
Usd Revenue--12866220472.00012209515465.000+5%13262292555.750-3%12784507177.750+1%12747107311.167+1%
Usd Total Gains Per Share--0.118-0.004+103%-0.008+107%0.078+52%0.144-18%
 EOD+4 -4MRQTTM+25 -9YOY+24 -115Y+21 -1410Y+21 -14

3.3 Fundamental Score

Let's check the fundamental score of Novartis AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1516.347
Price to Book Ratio (EOD)Between0-1103.326
Net Profit Margin (MRQ)Greater than00.252
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.317
Current Ratio (MRQ)Greater than10.931
Debt to Asset Ratio (MRQ)Less than10.570
Debt to Equity Ratio (MRQ)Less than11.332
Return on Equity (MRQ)Greater than0.151.587
Return on Assets (MRQ)Greater than0.050.679
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Novartis AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2,138.500
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Fundamental data was last updated by Penke on 2024-11-17 23:42:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Novartis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 25.2% means that $0.25 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novartis AG:

  • The MRQ is 25.2%. The company is making a huge profit. +2
  • The TTM is 33.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ25.2%TTM33.5%-8.3%
TTM33.5%YOY14.4%+19.1%
TTM33.5%5Y24.5%+9.0%
5Y24.5%10Y24.0%+0.6%
4.3.1.2. Return on Assets

Shows how efficient Novartis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • 67.9% Return on Assets means that Novartis generated $0.68 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novartis AG:

  • The MRQ is 67.9%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 82.7%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ67.9%TTM82.7%-14.8%
TTM82.7%YOY34.2%+48.5%
TTM82.7%5Y54.9%+27.8%
5Y54.9%10Y51.4%+3.5%
4.3.1.3. Return on Equity

Shows how efficient Novartis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • 158.7% Return on Equity means Novartis generated $1.59 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novartis AG:

  • The MRQ is 158.7%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 190.4%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ158.7%TTM190.4%-31.8%
TTM190.4%YOY71.0%+119.4%
TTM190.4%5Y119.2%+71.2%
5Y119.2%10Y109.6%+9.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Novartis AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Novartis is operating .

  • Measures how much profit Novartis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novartis AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY19.0%-19.0%
TTM-5Y20.3%-20.3%
5Y20.3%10Y20.8%-0.5%
4.3.2.2. Operating Ratio

Measures how efficient Novartis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.93 means that the operating costs are $0.93 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Novartis AG:

  • The MRQ is 0.935. The company is less efficient in keeping operating costs low.
  • The TTM is 1.015. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.935TTM1.015-0.081
TTM1.015YOY1.118-0.103
TTM1.0155Y1.086-0.071
5Y1.08610Y1.100-0.014
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Novartis AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Novartis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.93 means the company has $0.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Novartis AG:

  • The MRQ is 0.931. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.983. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.931TTM0.983-0.053
TTM0.983YOY1.175-0.192
TTM0.9835Y1.027-0.044
5Y1.02710Y1.047-0.020
4.4.3.2. Quick Ratio

Measures if Novartis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.32 means the company can pay off $0.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novartis AG:

  • The MRQ is 0.317. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.258. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.317TTM0.258+0.060
TTM0.258YOY0.504-0.246
TTM0.2585Y0.404-0.146
5Y0.40410Y0.382+0.021
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Novartis AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Novartis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novartis to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.57 means that Novartis assets are financed with 57.0% credit (debt) and the remaining percentage (100% - 57.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novartis AG:

  • The MRQ is 0.570. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.585. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.570TTM0.585-0.015
TTM0.585YOY0.512+0.074
TTM0.5855Y0.546+0.039
5Y0.54610Y0.529+0.018
4.5.4.2. Debt to Equity Ratio

Measures if Novartis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novartis to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 133.2% means that company has $1.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novartis AG:

  • The MRQ is 1.332. The company is able to pay all its debts with equity. +1
  • The TTM is 1.450. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.332TTM1.450-0.117
TTM1.450YOY1.054+0.395
TTM1.4505Y1.227+0.222
5Y1.22710Y1.156+0.071
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Novartis generates.

  • Above 15 is considered overpriced but always compare Novartis to the Drug Manufacturers - General industry mean.
  • A PE ratio of 14.15 means the investor is paying $14.15 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novartis AG:

  • The EOD is 16.347. Based on the earnings, the company is fair priced.
  • The MRQ is 14.150. Based on the earnings, the company is underpriced. +1
  • The TTM is 14.543. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD16.347MRQ14.150+2.197
MRQ14.150TTM14.543-0.394
TTM14.543YOY23.521-8.977
TTM14.5435Y21.555-7.012
5Y21.55510Y19.882+1.673
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novartis AG:

  • The EOD is 261.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 225.926. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 413.946. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD261.006MRQ225.926+35.080
MRQ225.926TTM413.946-188.020
TTM413.946YOY285.743+128.203
TTM413.9465Y379.355+34.590
5Y379.35510Y252.904+126.452
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Novartis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 89.44 means the investor is paying $89.44 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Novartis AG:

  • The EOD is 103.326. Based on the equity, the company is expensive. -2
  • The MRQ is 89.439. Based on the equity, the company is expensive. -2
  • The TTM is 84.594. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD103.326MRQ89.439+13.887
MRQ89.439TTM84.594+4.845
TTM84.594YOY62.298+22.296
TTM84.5945Y72.325+12.269
5Y72.32510Y62.397+9.928
4.6.2. Total Gains per Share

2.4. Latest News of Novartis AG

Does Novartis AG still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Novartis AG to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-10-29
21:11
Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest MoneymakerRead
2024-10-29
12:09
Novartis Lifts Guidance Again After Key Drugs Help ResultsRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in MXN. All numbers in thousands.

Summary
Total Assets97,505,000
Total Liabilities55,603,000
Total Stockholder Equity41,733,000
 As reported
Total Liabilities 55,603,000
Total Stockholder Equity+ 41,733,000
Total Assets = 97,505,000

Assets

Total Assets97,505,000
Total Current Assets25,693,000
Long-term Assets71,812,000
Total Current Assets
Cash And Cash Equivalents 7,903,000
Short-term Investments 532,000
Net Receivables 8,228,000
Inventory 5,747,000
Other Current Assets 3,031,000
Total Current Assets  (as reported)25,693,000
Total Current Assets  (calculated)25,441,000
+/- 252,000
Long-term Assets
Property Plant Equipment 10,622,000
Goodwill 25,234,000
Long Term Investments 2,126,000
Intangible Assets 27,775,000
Long-term Assets Other 1,655,000
Long-term Assets  (as reported)71,812,000
Long-term Assets  (calculated)67,412,000
+/- 4,400,000

Liabilities & Shareholders' Equity

Total Current Liabilities27,612,000
Long-term Liabilities27,991,000
Total Stockholder Equity41,733,000
Total Current Liabilities
Short Long Term Debt 7,532,000
Accounts payable 4,146,000
Other Current Liabilities 13,783,000
Total Current Liabilities  (as reported)27,612,000
Total Current Liabilities  (calculated)25,461,000
+/- 2,151,000
Long-term Liabilities
Long term Debt 19,663,000
Capital Lease Obligations Min Short Term Debt1,792,000
Long-term Liabilities Other 4,312,000
Long-term Liabilities  (as reported)27,991,000
Long-term Liabilities  (calculated)25,767,000
+/- 2,224,000
Total Stockholder Equity
Total Stockholder Equity (as reported)41,733,000
Total Stockholder Equity (calculated)0
+/- 41,733,000
Other
Capital Stock793,000
Common Stock Shares Outstanding 2,024,579
Net Debt 19,292,000
Net Invested Capital 68,928,000
Net Working Capital -1,919,000
Property Plant and Equipment Gross 10,622,000



6.2. Balance Sheets Structured

Currency in MXN. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
131,986,000
133,749,000
134,972,000
133,079,000
135,524,000
142,058,000
142,994,000
145,563,000
137,946,000
116,294,000
115,971,000
118,370,000
123,097,000
123,763,000
129,678,000
132,059,000
121,752,000
124,015,000
121,209,000
131,795,000
125,218,000
122,910,000
118,464,000
117,453,000
112,241,000
110,979,000
112,697,000
99,945,000
94,334,000
97,505,000
97,505,00094,334,00099,945,000112,697,000110,979,000112,241,000117,453,000118,464,000122,910,000125,218,000131,795,000121,209,000124,015,000121,752,000132,059,000129,678,000123,763,000123,097,000118,370,000115,971,000116,294,000137,946,000145,563,000142,994,000142,058,000135,524,000133,079,000134,972,000133,749,000131,986,000
   > Total Current Assets 
25,766,000
26,538,000
27,466,000
28,208,000
33,051,000
32,065,000
34,113,000
35,563,000
52,448,000
28,320,000
26,675,000
29,504,000
23,098,000
23,882,000
28,973,000
29,673,000
22,198,000
23,808,000
26,253,000
45,718,000
37,236,000
38,142,000
36,954,000
36,910,000
32,114,000
33,493,000
45,660,000
30,481,000
26,447,000
25,693,000
25,693,00026,447,00030,481,00045,660,00033,493,00032,114,00036,910,00036,954,00038,142,00037,236,00045,718,00026,253,00023,808,00022,198,00029,673,00028,973,00023,882,00023,098,00029,504,00026,675,00028,320,00052,448,00035,563,00034,113,00032,065,00033,051,00028,208,00027,466,00026,538,00025,766,000
       Cash And Cash Equivalents 
7,572,000
7,856,000
8,810,000
8,860,000
5,813,000
12,446,000
14,000,000
13,271,000
6,807,000
9,991,000
8,378,000
11,112,000
4,528,000
5,917,000
8,994,000
9,658,000
3,801,000
5,117,000
7,211,000
12,407,000
13,852,000
3,625,000
8,726,000
7,517,000
12,000,000
10,885,000
12,405,000
13,393,000
9,469,000
7,903,000
7,903,0009,469,00013,393,00012,405,00010,885,00012,000,0007,517,0008,726,0003,625,00013,852,00012,407,0007,211,0005,117,0003,801,0009,658,0008,994,0005,917,0004,528,00011,112,0008,378,0009,991,0006,807,00013,271,00014,000,00012,446,0005,813,0008,860,0008,810,0007,856,0007,572,000
       Short-term Investments 
572,000
564,000
589,000
594,000
580,000
514,000
541,000
2,563,000
305,000
344,000
339,000
334,000
445,000
376,000
1,876,000
1,905,000
276,000
239,000
951,000
15,706,000
4,962,000
16,133,000
10,377,000
11,413,000
260,000
289,000
290,000
569,000
225,000
532,000
532,000225,000569,000290,000289,000260,00011,413,00010,377,00016,133,0004,962,00015,706,000951,000239,000276,0001,905,0001,876,000376,000445,000334,000339,000344,000305,0002,563,000541,000514,000580,000594,000589,000564,000572,000
       Net Receivables 
8,234,000
8,381,000
8,482,000
10,557,000
9,116,000
8,989,000
8,766,000
10,925,000
7,612,000
7,973,000
7,826,000
10,229,000
8,795,000
7,952,000
8,299,000
9,963,000
8,481,000
8,654,000
8,632,000
9,563,000
8,678,000
8,910,000
8,680,000
9,801,000
8,916,000
9,195,000
6,819,000
7,107,000
7,840,000
8,228,000
8,228,0007,840,0007,107,0006,819,0009,195,0008,916,0009,801,0008,680,0008,910,0008,678,0009,563,0008,632,0008,654,0008,481,0009,963,0008,299,0007,952,0008,795,00010,229,0007,826,0007,973,0007,612,00010,925,0008,766,0008,989,0009,116,00010,557,0008,482,0008,381,0008,234,000
       Inventory 
6,583,000
6,901,000
6,954,000
6,867,000
7,227,000
7,097,000
6,952,000
6,956,000
5,728,000
6,094,000
6,123,000
5,982,000
6,398,000
6,904,000
7,136,000
7,131,000
6,997,000
7,111,000
6,885,000
6,666,000
6,997,000
6,880,000
6,779,000
7,175,000
7,886,000
8,228,000
5,610,000
5,913,000
5,743,000
5,747,000
5,747,0005,743,0005,913,0005,610,0008,228,0007,886,0007,175,0006,779,0006,880,0006,997,0006,666,0006,885,0007,111,0006,997,0007,131,0007,136,0006,904,0006,398,0005,982,0006,123,0006,094,0005,728,0006,956,0006,952,0007,097,0007,227,0006,867,0006,954,0006,901,0006,583,000
       Other Current Assets 
2,805,000
2,836,000
2,631,000
574,000
10,315,000
3,019,000
3,854,000
1,036,000
2,759,000
2,792,000
2,920,000
1,051,000
3,141,000
2,869,000
2,845,000
232,000
2,725,000
2,729,000
2,626,000
163,000
2,840,000
2,715,000
2,485,000
297,000
2,785,000
4,650,000
2,782,000
0
2,759,000
3,031,000
3,031,0002,759,00002,782,0004,650,0002,785,000297,0002,485,0002,715,0002,840,000163,0002,626,0002,729,0002,725,000232,0002,845,0002,869,0003,141,0001,051,0002,920,0002,792,0002,759,0001,036,0003,854,0003,019,00010,315,000574,0002,631,0002,836,0002,805,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
85,498,000
87,974,000
89,296,000
88,866,000
99,999,000
99,881,000
100,705,000
102,386,000
99,554,000
100,207,000
94,956,000
86,077,000
87,982,000
84,768,000
81,510,000
80,543,000
80,127,000
77,486,000
67,037,000
69,464,000
67,887,000
71,812,000
71,812,00067,887,00069,464,00067,037,00077,486,00080,127,00080,543,00081,510,00084,768,00087,982,00086,077,00094,956,000100,207,00099,554,000102,386,000100,705,00099,881,00099,999,00088,866,00089,296,00087,974,00085,498,00000000000
       Property Plant Equipment 
15,772,000
16,206,000
16,263,000
16,464,000
16,677,000
15,957,000
15,745,000
15,696,000
14,136,000
14,052,000
13,560,000
13,746,000
13,560,000
13,595,000
13,337,000
13,939,000
13,204,000
13,344,000
13,157,000
13,106,000
12,861,000
12,206,000
11,731,000
12,195,000
12,348,000
12,277,000
10,344,000
10,924,000
10,542,000
10,622,000
10,622,00010,542,00010,924,00010,344,00012,277,00012,348,00012,195,00011,731,00012,206,00012,861,00013,106,00013,157,00013,344,00013,204,00013,939,00013,337,00013,595,00013,560,00013,746,00013,560,00014,052,00014,136,00015,696,00015,745,00015,957,00016,677,00016,464,00016,263,00016,206,00015,772,000
       Goodwill 
31,197,000
31,606,000
31,715,000
31,750,000
34,128,000
35,167,000
35,042,000
35,294,000
26,295,000
26,533,000
26,306,000
26,524,000
28,937,000
29,100,000
29,532,000
29,999,000
29,590,000
29,766,000
29,572,000
29,595,000
29,636,000
29,113,000
28,668,000
29,301,000
29,481,000
29,522,000
23,416,000
23,341,000
23,063,000
25,234,000
25,234,00023,063,00023,341,00023,416,00029,522,00029,481,00029,301,00028,668,00029,113,00029,636,00029,595,00029,572,00029,766,00029,590,00029,999,00029,532,00029,100,00028,937,00026,524,00026,306,00026,533,00026,295,00035,294,00035,042,00035,167,00034,128,00031,750,00031,715,00031,606,00031,197,000
       Long Term Investments 
1,139,000
1,162,000
1,420,000
16,645,000
9,611,000
9,507,000
9,965,000
9,789,000
10,122,000
11,638,000
11,062,000
11,162,000
10,521,000
11,050,000
11,603,000
11,700,000
11,628,000
12,014,000
12,347,000
2,268,000
2,906,000
2,580,000
2,491,000
2,554,000
2,555,000
2,433,000
2,122,000
1,827,000
2,582,000
2,126,000
2,126,0002,582,0001,827,0002,122,0002,433,0002,555,0002,554,0002,491,0002,580,0002,906,0002,268,00012,347,00012,014,00011,628,00011,700,00011,603,00011,050,00010,521,00011,162,00011,062,00011,638,00010,122,0009,789,0009,965,0009,507,0009,611,00016,645,0001,420,0001,162,0001,139,000
       Intangible Assets 
31,529,000
31,473,000
30,836,000
24,705,000
32,122,000
39,443,000
37,947,000
23,672,000
27,021,000
27,221,000
29,694,000
28,787,000
37,451,000
36,669,000
36,883,000
36,809,000
35,377,000
34,818,000
33,951,000
34,182,000
34,853,000
33,367,000
31,888,000
31,644,000
30,451,000
28,003,000
26,418,000
26,879,000
26,272,000
27,775,000
27,775,00026,272,00026,879,00026,418,00028,003,00030,451,00031,644,00031,888,00033,367,00034,853,00034,182,00033,951,00034,818,00035,377,00036,809,00036,883,00036,669,00037,451,00028,787,00029,694,00027,221,00027,021,00023,672,00037,947,00039,443,00032,122,00024,705,00030,836,00031,473,00031,529,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
626,000
703,000
689,000
176,000
988,000
866,000
850,000
219,000
1,586,000
2,212,000
2,127,000
275,000
3,861,000
3,885,000
218,000
200,000
1,211,000
1,208,000
1,109,000
215,000
1,209,000
1,655,000
1,655,0001,209,000215,0001,109,0001,208,0001,211,000200,000218,0003,885,0003,861,000275,0002,127,0002,212,0001,586,000219,000850,000866,000988,000176,000689,000703,000626,00000000000
> Total Liabilities 
64,340,000
63,771,000
62,602,000
58,852,000
64,313,000
65,157,000
64,975,000
66,871,000
90,639,000
64,790,000
63,373,000
62,819,000
72,120,000
69,878,000
75,124,000
75,393,000
71,163,000
69,887,000
64,272,000
63,973,000
63,514,000
59,904,000
57,566,000
58,030,000
60,099,000
59,048,000
74,452,000
53,195,000
54,578,000
55,603,000
55,603,00054,578,00053,195,00074,452,00059,048,00060,099,00058,030,00057,566,00059,904,00063,514,00063,973,00064,272,00069,887,00071,163,00075,393,00075,124,00069,878,00072,120,00062,819,00063,373,00064,790,00090,639,00066,871,00064,975,00065,157,00064,313,00058,852,00062,602,00063,771,00064,340,000
   > Total Current Liabilities 
26,330,000
26,146,000
25,379,000
23,403,000
28,223,000
27,943,000
28,327,000
29,607,000
56,127,000
30,111,000
28,220,000
28,264,000
31,294,000
29,382,000
31,838,000
33,059,000
30,160,000
29,633,000
29,880,000
30,208,000
29,807,000
27,646,000
28,160,000
28,656,000
30,549,000
31,909,000
48,393,000
26,390,000
29,288,000
27,612,000
27,612,00029,288,00026,390,00048,393,00031,909,00030,549,00028,656,00028,160,00027,646,00029,807,00030,208,00029,880,00029,633,00030,160,00033,059,00031,838,00029,382,00031,294,00028,264,00028,220,00030,111,00056,127,00029,607,00028,327,00027,943,00028,223,00023,403,00025,379,00026,146,00026,330,000
       Short-term Debt 
31,257,000
30,561,000
30,160,000
466,000
10,911,000
9,596,000
9,177,000
3,248,000
7,428,000
7,857,000
8,017,000
6,846,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006,846,0008,017,0007,857,0007,428,0003,248,0009,177,0009,596,00010,911,000466,00030,160,00030,561,00031,257,000
       Short Long Term Debt 
31,257,000
30,561,000
30,160,000
466,000
10,911,000
9,596,000
9,177,000
3,248,000
7,428,000
7,857,000
8,017,000
6,846,000
10,956,000
8,875,000
9,727,000
9,591,000
10,165,000
9,075,000
9,337,000
6,227,000
6,696,000
7,045,000
7,055,000
5,931,000
6,968,000
8,289,000
5,458,000
6,084,000
8,339,000
7,532,000
7,532,0008,339,0006,084,0005,458,0008,289,0006,968,0005,931,0007,055,0007,045,0006,696,0006,227,0009,337,0009,075,00010,165,0009,591,0009,727,0008,875,00010,956,0006,846,0008,017,0007,857,0007,428,0003,248,0009,177,0009,596,00010,911,000466,00030,160,00030,561,00031,257,000
       Accounts payable 
4,566,000
4,691,000
4,685,000
5,169,000
4,994,000
5,486,000
4,970,000
5,556,000
4,638,000
4,752,000
4,669,000
5,424,000
4,828,000
4,820,000
4,705,000
5,403,000
5,040,000
4,811,000
4,665,000
5,553,000
5,083,000
4,969,000
4,693,000
5,146,000
5,426,000
5,350,000
3,870,000
4,926,000
4,062,000
4,146,000
4,146,0004,062,0004,926,0003,870,0005,350,0005,426,0005,146,0004,693,0004,969,0005,083,0005,553,0004,665,0004,811,0005,040,0005,403,0004,705,0004,820,0004,828,0005,424,0004,669,0004,752,0004,638,0005,556,0004,970,0005,486,0004,994,0005,169,0004,685,0004,691,0004,566,000
       Other Current Liabilities 
13,440,000
13,893,000
13,697,000
8,060,000
12,318,000
12,861,000
14,180,000
9,210,000
5,104,000
50,000
24,000
10,383,000
15,261,000
15,429,000
17,139,000
12,082,000
14,676,000
15,468,000
15,601,000
12,936,000
17,756,000
15,374,000
16,164,000
11,941,000
14,938,000
34,000
22,764,000
105,000
15,012,000
13,783,000
13,783,00015,012,000105,00022,764,00034,00014,938,00011,941,00016,164,00015,374,00017,756,00012,936,00015,601,00015,468,00014,676,00012,082,00017,139,00015,429,00015,261,00010,383,00024,00050,0005,104,0009,210,00014,180,00012,861,00012,318,0008,060,00013,697,00013,893,00013,440,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
34,512,000
34,679,000
35,153,000
34,555,000
40,826,000
40,496,000
43,286,000
42,334,000
41,003,000
40,254,000
34,392,000
33,765,000
33,707,000
32,258,000
29,406,000
29,374,000
29,550,000
27,139,000
26,059,000
26,805,000
25,290,000
27,991,000
27,991,00025,290,00026,805,00026,059,00027,139,00029,550,00029,374,00029,406,00032,258,00033,707,00033,765,00034,392,00040,254,00041,003,00042,334,00043,286,00040,496,00040,826,00034,555,00035,153,00034,679,00034,512,00000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
1,937,000
2,046,000
1,968,000
1,949,000
1,939,000
1,956,000
1,951,000
2,005,000
1,931,000
1,942,000
1,891,000
1,896,000
1,849,000
1,810,000
1,751,000
1,789,000
1,840,000
1,792,000
1,663,000
1,828,000
1,754,000
1,792,000
1,792,0001,754,0001,828,0001,663,0001,792,0001,840,0001,789,0001,751,0001,810,0001,849,0001,896,0001,891,0001,942,0001,931,0002,005,0001,951,0001,956,0001,939,0001,949,0001,968,0002,046,0001,937,00000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
1,213,000
0
0
0
1,393,000
0
0
0
1,475,000
0
0
0
1,578,000
4,838,000
0
4,081,000
1,193,000
4,259,000
4,312,000
4,312,0004,259,0001,193,0004,081,00004,838,0001,578,0000001,475,0000001,393,0000001,213,00000000000000
       Deferred Long Term Liability 
0
0
0
5,292,000
0
0
0
15,047,000
0
0
0
5,424,000
0
0
0
4,700,000
0
0
0
5,499,000
0
0
0
4,421,000
0
0
0
0
0
0
0000004,421,0000005,499,0000004,700,0000005,424,00000015,047,0000005,292,000000
> Total Stockholder Equity
67,586,000
69,919,000
72,311,000
74,168,000
71,098,000
76,815,000
77,938,000
78,614,000
47,229,000
51,426,000
52,524,000
55,474,000
50,903,000
53,812,000
54,484,000
56,598,000
50,523,000
54,042,000
56,771,000
67,655,000
61,540,000
62,925,000
60,820,000
59,342,000
52,059,000
51,847,000
38,164,000
46,667,000
39,675,000
41,733,000
41,733,00039,675,00046,667,00038,164,00051,847,00052,059,00059,342,00060,820,00062,925,00061,540,00067,655,00056,771,00054,042,00050,523,00056,598,00054,484,00053,812,00050,903,00055,474,00052,524,00051,426,00047,229,00078,614,00077,938,00076,815,00071,098,00074,168,00072,311,00069,919,00067,586,000
   Common Stock
67,586,000
69,919,000
72,311,000
969,000
969,000
944,000
944,000
944,000
944,000
936,000
936,000
936,000
936,000
913,000
913,000
913,000
913,000
913,000
901,000
901,000
901,000
890,000
890,000
890,000
0
0
0
0
0
0
000000890,000890,000890,000901,000901,000901,000913,000913,000913,000913,000913,000936,000936,000936,000936,000944,000944,000944,000944,000969,000969,00072,311,00069,919,00067,586,000
   Retained Earnings Total Equity000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 0000-4,625,0000-4,996,000-4,543,000-3,337,000-2,752,000-4,187,000-1,520,000-1,206,000-2,378,000-1,419,000-3,788,000-4,559,000-5,321,000-4,657,000-6,260,000-5,088,000-5,170,000-4,452,000-3,092,000-3,859,000-3,276,000-4,340,000000



6.3. Balance Sheets

Currency in MXN. All numbers in thousands.




6.4. Cash Flows

Currency in MXN. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in MXN. All numbers in thousands.

Gross Profit (+$)
totalRevenue46,660,000
Cost of Revenue-12,472,000
Gross Profit34,188,00034,188,000
 
Operating Income (+$)
Gross Profit34,188,000
Operating Expense-36,891,000
Operating Income9,769,000-2,703,000
 
Operating Expense (+$)
Research Development11,371,000
Selling General Administrative12,517,000
Selling And Marketing Expenses-
Operating Expense36,891,00023,888,000
 
Net Interest Income (+$)
Interest Income627,000
Interest Expense-855,000
Other Finance Cost-191,000
Net Interest Income-419,000
 
Pretax Income (+$)
Operating Income9,769,000
Net Interest Income-419,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)9,123,0009,996,000
EBIT - interestExpense = -855,000
14,850,000
15,705,000
Interest Expense855,000
Earnings Before Interest and Taxes (EBIT)-9,978,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax9,123,000
Tax Provision-551,000
Net Income From Continuing Ops8,572,0008,572,000
Net Income14,850,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-227,000419,000
 

Technical Analysis of Novartis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novartis. The general trend of Novartis is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novartis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novartis AG.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2,237 < 2,237 < 2,237.

The bearish price targets are: 2,149 > 2,149 > 2,149.

Tweet this
Novartis AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novartis AG. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novartis AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novartis AG.

Novartis AG Daily Moving Average Convergence/Divergence (MACD) ChartNovartis AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novartis AG. The current adx is .

Novartis AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novartis AG.

Novartis AG Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novartis AG.

Novartis AG Daily Relative Strength Index (RSI) ChartNovartis AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novartis AG.

Novartis AG Daily Stochastic Oscillator ChartNovartis AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novartis AG.

Novartis AG Daily Commodity Channel Index (CCI) ChartNovartis AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novartis AG.

Novartis AG Daily Chande Momentum Oscillator (CMO) ChartNovartis AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novartis AG.

Novartis AG Daily Williams %R ChartNovartis AG Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novartis AG.

Novartis AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novartis AG.

Novartis AG Daily Average True Range (ATR) ChartNovartis AG Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novartis AG.

Novartis AG Daily On-Balance Volume (OBV) ChartNovartis AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novartis AG.

Novartis AG Daily Money Flow Index (MFI) ChartNovartis AG Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novartis AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Novartis AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novartis AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2,138.500
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Novartis with someone you think should read this too:
  • Are you bullish or bearish on Novartis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novartis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novartis AG

I send you an email if I find something interesting about Novartis AG.


Comments

How you think about this?

Leave a comment

Stay informed about Novartis AG.

Receive notifications about Novartis AG in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.